血清肿瘤标志物与表皮生长因子受体突变及靶向治疗相关性的研究进展

摘要

Compared with traditional chemotherapy , the tumor molecular targeting therapy has higher selectivity and less adverse reactions.The application of the epidermal growth factor receptor tyrosine kinase inhibitors( EGFR-TKI) has a rapid development in lung cancer and the curative effect of targeted drugs has drawn great attention.EGFR mutation status is the predictive factor in the treatment of advanced non-small cell lung cancer(NSCLC) and the precondition of EGFR-TKIs′application.However,because of the exist-ence of various objective factors,the clinical promotion of EGFR mutation detection is limited .Therefore,it′s of great significant value to find biomarkers to replace or supplement the EGFR mutation test .%与传统的化疗相比肿瘤分子靶向治疗具有更高的选择性和较少的不良反应。表皮生长因子受体（ EGFR）酪氨酸激酶抑制剂（ EGFR-TKI）在肺癌中的应用得到了迅速发展，其在靶向药物中的疗效受到了极大的关注。 EGFR的突变状态是EGFR-TKI治疗晚期非小细胞肺癌（ NSCLC）的疗效预测因子，是使用靶向药物的先决条件。然而，由于各种客观因素的存在使得 EGFR 突变检测的临床推广受到限制，因此寻找可能替代或辅助EGFR突变检测的生物标志物具有非常重要的价值。